Business Wire

CARBIOS

8.2.2023 06:51:15 CET | Business Wire | Press release

Share
Carbios appoints four new Board members to strengthen international expertise in brand development, business growth and scientific research

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005964/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Clockwise from left: Mateus SCHREINER GARCEZ LOPES, Sandrine CONSEILLER, Prof. Karine AUCLAIR & Amandine DE SOUZA

Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, announces the appointment of four new members to its Board of Directors.

Prof. Karine AUCLAIR, professor of Chemistry at McGill University, Sandrine CONSEILLER, former CEO of Aigle, Amandine DE SOUZA, General Manager of LE BHV MARAIS, Eataly and Home, DIY and Leisure Purchasing at Galeries Lafayette Group, and Mateus SCHREINER GARCEZ LOPES, Global Director for Energy Transition and Investments at Raizen, have all been appointed members of Carbios’ Board of Directors. Three of the new members have strong, proven expertise in various industries covering fashion, retail and energy, as well as business development and senior executive management in high-growth markets and sectors around the world. The new scientific expertise will also help enhance and advance Carbios’ research into biological solutions for the life cycle of plastics and textiles. In addition, a sensitivity to CSR issues and proven results in this field was also a key selection factor to join the Board. The new members’ combined strategic vision, solid industry experience and CSR commitments will support Carbios in its industrial and commercial plans.

In the new structure, Prof. Karine AUCLAIR succeeds Jacqueline LECOURTIER, Sandrine CONSEILLER succeeds Jean FALGOUX, Amandine DE SOUZA succeeds Alain CHEVALLIER, and Mateus SCHREINER GARCEZ LOPES succeeds Jean-Claude LUMARET.

“We wish to thank Jacqueline Lecourtier, Jean Falgoux, Alain Chevallier and Jean-Claude Lumaret for their strong contribution to Carbios over the years, helping the company to grow from the early R&D phase to pre-commercial stage. As Carbios now moves towards its industrial and commercial stage, and prepares internationalization, bringing new expertise to the Board is key to success,” commented Philippe POULETTY, Chairman of Carbios’ Board of Directors. “Furthermore the election of three new female board members, Prof. Karine Auclair, Sandrine Conseiller and Amandine De Souza, along with Mateus Schreiner Garcez Lopes, all with stellar professional and complementary backgrounds, and who share our passion to help clean the planet with radical innovation, is a strong signal of Carbios’ commitment to ESG criteria.”

APPOINTMENTS TO THE BOARD OF DIRECTORS

Prof. Karine AUCLAIR is Professor of Chemistry at McGill University and holds the Tier 1 Canada Research Chair in Antimicrobials and Green Enzymes. She has received numerous awards over the years, including the Clara Benson Award of the Canadian Society of Chemistry, the McGill Tomlinson Professorship, the Leo Yaffe Teaching Award, and the McGill Fessenden Professorship, to name a few. She is an internationally recognized bioorganic chemist with significant scientific contributions to the fields of antimicrobial resistance, biocatalysis and enzymology. Her research led to several patents notably in the clean enzymatic depolymerization of untreated, high crystallinity PET plastics for closed-loop recycling. Her work has been published in nearly 100 peer-reviewed publications in high-impact journals, and often highlighted by the media. As a recognized leader in her field, she is often invited to speak at industrial and academic conferences around the world, and to review theses and grant applications for worldwide institutions.

Prof. Karine AUCLAIR: “From my expertise with enzymes in moist-solid mixtures, I am excited to join the Board of Carbios and contribute to the development and growth of plastic biorecycling and biodegradation.”

Sandrine CONSEILLER is former Chief Executive Officer of Aigle (the emblematic French brand committed to sustainable fashion). Prior to joining Aigle, Sandrine was Group Marketing & Branding Executive Vice-President at Lacoste (another historic French fashion brand) from 2011 to 2015. She contributed to the Lacoste maison turnaround with strong growth and numerous professional awards including several Cannes Lions Awards. She was also Member of the Executive Board. Sandrine began her career at Unilever and spent 20 years leading global businesses within various divisions, mainly in Personal Care, in Latin America, Europe, and Asia. Sandrine is also Member of the Board of Phildar (the iconic French knitwear brand), Member of the Board of Raise Sherpa (the first philantropic endowment fund dedicated to start-ups) and is a funding partner of NEO FOUNDERS (a venture fund mentoring impact start-ups).

Sandrine CONSEILLER: “I feel privileged and humbled to join Carbios’ Board of Directors and take part in a transformative adventure that will impact both the fashion and beauty industries, as well as the world we will leave for our children.”

Amandine DE SOUZA is General Manager of LE BHV MARAIS (French retail, decoration and fashion department stores), Eataly (an Italian gastronomy concept franchise) and Home, DIY and Leisure Purchasing at Galeries Lafayette Group since 2018. She has been a Member of its Executive Committee since 2020. Amandine has 17 years' experience in different types of companies of various sizes: from family business, to start-up, and multinational. She was General Manager for France at Westwing (an e-commerce start-up) from 2015 to 2018. From 2009 to 2015, she was International Merchandise Director at Casino Group (food and non-food retail distribution). Prior to this, she worked as a strategic consultant at Bain & Company within their Distribution and Consumer Goods Division in France and internationally.

Amandine DE SOUZA: “I am delighted to join the Board of Carbios, an extremely innovative company tackling the major issue of plastic pollution. I will be working alongside the company to support its international development and find the best ways to enhance its performance.”

Mateus SCHREINER GARCEZ LOPES is Global Director for Energy Transition and Investments at Raizen (global leader in bioenergy from Brazil), leading technology, new business development and intellectual property at the company. He was previously Global Manager for Innovation and Business Development in Renewable Chemicals at Braskem (the largest producer of thermoplastic resins in the Americas and the world’s largest producer of biopolymers). Before his transition to the corporate world, Mateus held several researcher and lecturer positions on Synthetic Biology and metabolic Engineering at Universities in Mexico, Germany, United States and Brazil. He is also a Board Member of Iogen Energy Corporation, Vice-Chairman of the Board of the Brazilian Association of Bio Innovation, and Advisory Committee Member from the MIT Energy Initiative.

Mateus SCHREINER GARCEZ LOPES: “I am thrilled to be involved in Carbios’ mission of reshaping the plastics and textile industries with circular processes. Carbios has a world-class team of scientists and entrepreneurs, and by joining the Board, my expertise in bringing new renewable technologies to market will help to design its R&D and commercialization strategy.”

Members of Carbios’ Board of Directors:

  • Dr. Philippe POULETTY, Chairman
  • Prof. Karine AUCLAIR
  • Sandrine CONSEILLER
  • Prof. Juan DE PABLO
  • Amandine DE SOUZA
  • Vincent KAMEL
  • Emmanuel LADENT
  • Isabelle PARIZE
  • Laurent SCHMITT, representative for BOLD (Business Opportunities for l’Oréal Development)
  • Mateus SCHREINER GARCEZ LOPES
  • Nicolas SEEBOTH, representative for Michelin Ventures
  • Alen VUKIC, censor

Visit the Carbios website for individuel Board Member biographies: https://www.carbios.com/en/governance/

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.

For more information, please visit www.carbios.com/en / Twitter: Carbios LinkedIn: Carbios Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the English version shall prevail

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005964/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye